Bristol Myers Squibb reports data from Phase III multiple sclerosis trial

Bristol Myers Squibb (BMS) has unveiled the latest data from the Phase III DAYBREAK clinical trial, highlighting the long-term efficacy and safety profile of Zeposia (ozanimod) in treating patients with relapsing forms of multiple sclerosis (MS).